<DOC>
	<DOC>NCT01888575</DOC>
	<brief_summary>This study is conducted in a cohort of low dose aspirin (ASA) users previously ascertained .The aims of the post hoc analyses are: To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use versus non-use, crude and adjusted by confounding. To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use stratified by age and sex. To evaluate other predictors of discontinuation of low-dose ASA during the first year of ASA therapy.</brief_summary>
	<brief_title>Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy</brief_title>
	<detailed_description>Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy for secondary prevention</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Patients aged 5084 years in 20002007. Patients with first prescription of low dose ASA ( see study population description). Patients were required to have been enrolled with their primary care practitioner (PCP) for at least 2 years and to have a computerized prescription history of at least 1 year before the start of the study. Patients aged below age 50 and 85 years and above ( see study population description). Patients with a diagnosis of cancer, alcohol abuse or alcoholrelated disease. Incomplete data recording in THIN.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Discontinuation of low dose ASA,</keyword>
	<keyword>Secondary cardiovascular prevention,</keyword>
	<keyword>Acid-suppressing drugs,</keyword>
	<keyword>Gastrointestinal risk,</keyword>
	<keyword>Epidemiology</keyword>
</DOC>